Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Company Overview

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing oral dosage-form products. The company’s portfolio includes generic and proprietary immediate-release and controlled-release tablets and capsules, with an emphasis on products that use abuse-deterrent or other specialized drug-delivery technologies.

Elite has developed and commercialized products in several therapeutic categories, including pain management and other prescription medicines. Its activities include product formulation, development, regulatory support, manufacturing, and partnering or licensing arrangements intended to expand the availability of its products in the United States.

Based in Northvale, New Jersey, Elite operates primarily in the U.S. pharmaceutical market. The company is led by Nasrat Hakim, who serves as chairman and chief executive officer. Elite’s business has historically centered on building a portfolio of niche generic and specialty pharmaceutical products while maintaining development and manufacturing capabilities for oral medicines.

Key Stats

• Today's Range: $0.25 to $0.26
• 50-Day Range: $0.25 to $0.39
• 52-Week Range: $0.24 to $0.69
• Volume: 509,516 shs
• Average Volume: 621,800 shs
• Market Capitalization: $278.01 million
• P/E Ratio: 6.45
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Elite Pharmaceuticals Stock Analysis - MarketRank™

Elite Pharmaceuticals scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elite Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elite Pharmaceuticals is 6.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elite Pharmaceuticals is 6.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.

Price to Book Value per Share Ratio

Elite Pharmaceuticals has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.28% of the float of Elite Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Elite Pharmaceuticals has a short interest ratio ("days to cover") of 1.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elite Pharmaceuticals has recently increased by 2.31%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elite Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Elite Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Elite Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Elite Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for ELTP on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

1 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.01% of the stock of Elite Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ELTP
• CIK: 1053369
• Web: www.elitepharma.com
• Phone: (201) 750-2646
• Fax: 201-750-2755
• Employees: 65
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 6.45
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $44.87 million
• Net Margins: 40.19%
• Pretax Margin: 46.16%
• Return on Equity: 44.58%
• Return on Assets: 29.54%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 3.76
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $148.87 million
• Price / Sales: 1.87
• Cash Flow: $0.03 per share
• Price / Cash Flow: 9.67
• Book Value: $0.09 per share
• Price / Book: 2.87

Miscellaneous

• Outstanding Shares: 1,077,140,000
• Free Float: 921,813,000
• Market Cap: $278.01 million
• Optionable: Not Optionable
• Beta: 0.37